wherein

R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;

x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;

R_1, R_2, and R_3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or

R_2 and R_3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, depression, bipolar disorder, or obesity in a subject in need thereof.

[0004b] In another aspect, the present disclosure refers to of a compound of Formula I:



I

wherein

R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;

x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;

R_1, R_2, and R_3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or

R_2 and R_3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle

What is claimed is:

1. Use of a compound of Formula I:



I

wherein

R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;

x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;

R_1, R_2, and R_3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or

R_2 and R_3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, depression, bipolar disorder, or obesity in a subject in need thereof.

2. Use of a compound of Formula I:



I

wherein

R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R_1, R_2, and R_3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or
R_2 and R_3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inducing a pro-cognitive effect in a subject in need thereof.

3. The use of claim 2, wherein the subject has bipolar depression, major depressive disorder, schizoaffective disorders, PTSD, Alzheimer's Disease, Parkinson's Disease, dementia, or multiple sclerosis.

4. Use of a compound of Formula I:



I

wherein
R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R_1, R_2, and R_3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or

R_2 and R_3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating nightmares and/or sleep-related disturbances associated with PTSD in a subject in need thereof.

5. The use of any one of claims 1-4, wherein the compound is a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof.

6. The use of any one of claims 1-4, wherein the compound is compound 1:



1

or a pharmaceutically acceptable salt thereof.

7. The use of any one of claims 1-4, wherein the compound is compound 2:



2

or a pharmaceutically acceptable salt thereof.

8. The use of any one of claims 1-7, comprising a composition to be administered comprising the compound.

9. The use of any one of claims 1-7, comprising a pharmaceutical composition to be administered comprising the compound and a pharmaceutically acceptable carrier.

10. The use of claim 8 or 9, wherein the composition is a dosage form.

11. The use of claim 10, wherein the composition is an immediate release oral dosage form.

12. The use of claim 11, wherein the composition is a tablet or a capsule.